Tuesday, July 21st, 2009

New England Tech Stock Index
Boston Scientific’s way up, VC deals are way down, and Epix is down and out in today’s NewsFlash roundup. Also, News editor Rodney Brown drops by Draper Lab’s Apollo 11 anniversary party.
• Boston Scientific profits up 60%
The Natick-based manufacturer of medical devices had revenue of $2.07 billion in the second quarter of this year, up slightly from $2.02 billion in the second quarter of 2008. Net income increased to $158 million from $98 million a year earlier.
• Epix to liquidate assets
The Lexington-based company’s officials said that the company was unable to raise enough money or enter into a partnership in time and that it has entered into an Assignment for the Benefit of Creditors. The purpose of the Assignment is to conclude the company’s operations and provide for an orderly liquidation of its assets.
• New NVCA data reveals fewer Q2 VC deals, slower recovery
Numbers reported this morning by the NVCA and PricewaterhouseCoopers LLP were considerably less optimistic, showing $3.7 million invested over 612 deals. While Dow Jones analysts predicted a “rebound” in the venture investing sector, the NVCA says figures for the full year will most likely reflect a setback to 1996 and 1997 levels of $11 billion to $14 billion. (more…)
Tags: Akiba, AMSC, Apollo 11, Aveo Pharmaceuticals, Belden, Boston Scientific, Draper Lab, Epix Pharmaceuticals, First Wind, NASA, Raytheon, SEC, stimulus, Third Rock, VCs
Posted in Defense, Energy, Entrepreneurship, Envirotech, Financial Services, Hardware, IT, Internet, Legislation, Life Sciences, Manufacturing, Massachusetts, Personnel, Public Policy, Recovery, Software, Startups | No Comments »
Monday, June 29th, 2009
Shares drop, lawsuits grow and personnel move in today’s NewsFlash Roundup:
• Bhatia, Best, Kivel join Aura Biosciences advisory boards
Aura Biosciences, a Cambridge-based biotechnology company focused on new drug delivery methods, has added three Boston-area advisors to its leadership team.
• Biogen shares drop on 10th Tysabri PML case
Shares of Biogen Idec Inc. sank Monday after the biotechnology giant confirmed that another patient taking the multiple sclerosis drug Tysabri has been diagnosed with a potentially fatal brain infection called progressive multifocal leukoencephalopathy, or PML.
• New funding, CEO and HQ for CloudSwitch
Former SolidWorks Corp. CEO John McEleney will join the company along with the round of funding, which was led by new investors Commonwealth Capital Ventures, and increase the total amount invested in Cloudswitch to $15.4 million. (more…)
Tags: Alnylam, Aura Biosciences, Boston Scientific, CloudSwitch, Commonwealth Capital Ventures, Forma Therapeutics, GI Dynamics, Hepregen, John McEleney, Kenneth Bair, Lawrence Best, Massachusetts Technology Collaborative, Max Planck Society, MIT, Richard Kivel, Sangeeta Bhatia, Theragenetics, UMass, Whitehead Institute
Posted in Education & Training, Energy, Entrepreneurship, Envirotech, IT, Internet, Life Sciences, Massachusetts, Networks, Public Policy, Software, Startups | No Comments »